Provided by Tiger Trade Technology Pte. Ltd.

Passage Bio, Inc.

9.01
-0.4400-4.66%
Post-market: 9.010.00000.00%16:04 EST
Volume:70.84K
Turnover:654.95K
Market Cap:28.64M
PE:-0.62
High:9.70
Open:9.23
Low:8.64
Close:9.45
52wk High:20.20
52wk Low:5.12
Shares:3.18M
Float Shares:2.87M
Volume Ratio:1.16
T/O Rate:2.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.5667
EPS(LYR):-21.4442
ROE:-87.18%
ROA:-31.66%
PB:0.92
PE(LYR):-0.42

Loading ...

Chardan Raises Price Target on Passage Bio to $21 From $6, Keeps Buy Rating

MT Newswires Live
·
Nov 12

Passage Bio Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 12

Passage Bio (PASG) Receives a Buy from Chardan Capital

TIPRANKS
·
Nov 12

Wedbush Adjusts Passage Bio Price Target to $32 From $40, Maintains Outperform Rating

MT Newswires Live
·
Nov 12

Passage Bio Unveils Gene Therapy Advances Targeting Neurodegenerative Diseases

Reuters
·
Nov 11

Passage Bio reports Q3 net loss of $7.7 million on $52.8 million cash balance

Reuters
·
Nov 11

Passage Bio Inc - Cash Runway Extended Into Q1 2027

THOMSON REUTERS
·
Nov 11

Passage Bio Inc - Net Loss of $2.44 per Share for Q3 2025

THOMSON REUTERS
·
Nov 11

Passage Bio Inc - on Track to Obtain Regulatory Feedback on Ftd-Grn Registrational Trial Design in 1H 2026

THOMSON REUTERS
·
Nov 11

Passage Bio Inc expected to post a loss of $2.80 a share - Earnings Preview

Reuters
·
Nov 07

Passage Bio CEO to Join Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

Reuters
·
Nov 05

Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference

GlobeNewswire
·
Oct 14

Weston Nichols Reports Acquisition of Common Shares of Passage Bio Inc

Reuters
·
Sep 16

Passage Bio Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Aug 15

Passage Bio Inc : Wedbush Adjusts Target Price to $40 From $3 to Reflect 1-for-20 Reverse Stock Split

THOMSON REUTERS
·
Aug 13

Passage Bio Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases

Reuters
·
Aug 12

Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate

Benzinga
·
Aug 12

Passage Bio Inc - Cash Runway Extended Into 1Q 2027

THOMSON REUTERS
·
Aug 12

Passage Bio Inc expected to post a loss of $4.05 a share - Earnings Preview

Reuters
·
Aug 09

Passage Bio Inc expected to post a loss of $4.05 a share - Earnings Preview

Reuters
·
Aug 04